Royalty Pharma PLC (MEX:RPRX)
MXN 528.5 0 (0%) Market Cap: 229.61 Bil Enterprise Value: 416.39 Bil PE Ratio: 10.02 PB Ratio: 1.66 GF Score: 72/100

Cytokinetics Inc and Royalty Pharma Funding Agreements Call Transcript

Jan 07, 2022 / 01:30PM GMT
Release Date Price: MXN833.34
Operator

Good morning, and welcome, ladies and gentlemen, to the Cytokinetics conference call. At this time, I would like to inform you that this call is being recorded (Operator Instructions).

I will now turn the call over to Joanna Siegall, Cytokinetics' Senior Manager of Corporate Communications and Investor Relations. Please go ahead.

Joanna Siegall

Good morning, everyone, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will begin with an overview of today's announcement regarding the structured financing with Royalty Pharma; then Ching Jaw, our SVP and Chief Financial Officer, will summarize the financial terms of each transaction, and will review our revised financial outlook. Robert will then provide final comments before opening the call for questions. At that time, we'll be joined by Fady Malik, EVP, Research and Development; Libby Schnieders, SVP, Business Development; and Andrew Callos, EVP and Chief Commercial Officer.

Please note that portions of the following discussion, including our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot